OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, announces that it has signed and closed an asset purchase transaction to acquire a custom-built, state-of-the-art cell and gene therapy viral vector manufacturing facility in North Carolina from RTP Operating, LLC, a subsidiary of National Resilience Holdco, Inc. (Resilience). The acquisition expands OXB’s viral vector manufacturing capabilities in the US up to commercial-scale, increasing GMP capacity and enhancing services to clients across North America. The FDA approved facility in Durham, North Carolina adds scalable vector manufacturing capabilities and end-to-end services across drug substance and fill-finish.
Read the full article: OXB Expands US Footprint with Acquisition of Commercial-Scale Viral Vector Facility in North Carolina //
Source: https://www.globenewswire.com/news-release/2025/10/07/3162366/0/en/OXB-expands-US-footprint-with-acquisition-of-commercial-scale-viral-vector-facility-in-North-Carolina.html